logo
Cannabis Compound Could Protect Us From Deadly Fungal Disease

Cannabis Compound Could Protect Us From Deadly Fungal Disease

Yahoo3 days ago

A dangerous fungal pathogen has proven no match for what may be one of the most useful plants in nature.
Scientists studying the chemical properties of cannabis have found it kills one of the most dangerous fungal pathogens in the world – in a laboratory setting, at least.
Cryptococcus neoformans, a species of fungus behind cryptococcosis and cryptococcal meningitis, appears to be vulnerable to topical treatment with cannabidiol and cannabidivarin, compounds found in the plant Cannabis sativa.
"When Cryptococcus neoformans gets to your central nervous system, it causes life-threatening meningitis," explains biologist Hue Dinh of Macquarie University in Australia. "The mortality rate is very high, and it's really hard to treat."
Fungal pathogens pose a pretty significant threat to human health, with around 300 species known to cause diseases in humans, with varying levels of severity. Because pathogens such as fungi and bacteria continually develop resistances to drugs, new treatment options are continually needed to keep them at bay.
One strategy is to look at medications that have already been approved for human use for other ailments. Dinh and her colleagues turned their research to cannabis, isolating five compounds to test on C. neoformans and a range of other pathogens.
They isolated the fungal species in a lab, and applied the compounds. Cannabidiol (CBD), which is non-psychoactive, and cannabidivarin (CBDV), which is psychoactive, both killed C. neoformans adroitly, acting even faster than current antifungal treatments. They were also effective at eradicating the fungal pathogens responsible for such conditions as jock itch and athlete's foot.
"Proteomics analysis revealed that the antifungal activity of CBD and CBDV was linked to destabilization of the membrane, alterations in ergosterol biosynthesis, disruption of metabolic pathways, as well as selective involvement of mitochondrial-associated proteins," the researchers wrote in their paper.
It's one thing to kill a fungus in a petri dish, but quite another to observe the treatment working in a living system. To test their findings further, the researchers turned to Galleria mellonella, the greater wax moth.
The larvae of this moth possess an innate immune response that is similar to that of mammals. They are also inexpensive to obtain, have short lifespans, and require no special equipment to keep, making them an excellent model for large-scale studies of infectious pathogens and the treatments thereof.
Moth larvae were given small burn wounds, and then divided into groups. One group was left alone with just the burn wounds as a control; the remainder were infected with C. neoformans, and treated with different medicaments.
One group was treated with CBD dissolved in dimethyl sulfide. Another group was treated with dimethyl sulfide without the CBD. Finally, the last group was treated using Amphotericin B, a medication used to treat serious fungal infections in humans.
The results were striking. The survival rate of the larvae treated with CBD was significantly higher than the survival rate of the larvae treated with the dimethyl sulfide alone, and also higher than the survival rate of the Amphotericin B group.
In fact, it was nearly as high as the survival rate of the control group – the larvae that had not been infected with the fungus at all.
Although the treatment of infections that reach the lungs and brain is a bit more complicated, the result suggests that, at the very least, the topical application of cannabidiol might be effective at treating a range of fungal skin infections.
"If we can demonstrate that these ones work well for common infections," Dinh says, "you could actually just get some CBD oil and then rub it on your skin to treat it."
The research has been published in PLOS Neglected Tropical Diseases.
Pooping Is a High-Stakes Event That Could Be Fatal For One Group
Misophonia Has Genetic Links to Depression And Anxiety, Study Finds
Experimental Drug Helped Cancer Patients Live 40% Longer in Clinical Trial

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Americans lose it over these tiny everyday annoyances
Americans lose it over these tiny everyday annoyances

Miami Herald

time13 hours ago

  • Miami Herald

Americans lose it over these tiny everyday annoyances

Simply spotting a nemesis, loud chewing and heavy breathing are some of the smallest things that will push Americans over the edge, according to new research. A survey asked 2,000 adults about their lowest common denominator of stress and revealed that the smallest sounds or acts are enough to send their anxiety skyrocketing. Lagging WiFi (40%) and an unexpected phone call (35%) also ranked high on the list. Americans outlined some of the weirdest causes of stress: "the texture of my socks," "aluminum cans," "not washing my hair for two days" and "the beeping sound on TV to hide swearing" were among the most unique. To pile on, just thinking about how expensive everything has gotten (47%), running late when stuck in traffic (40%) and simple miscommunications (39%) are common stressful situations. Conducted by Talker Research on behalf of CBDfx, results also revealed what Americans do when they need to mellow out. Many turn to music (58%), deep breathing and meditation (34%) or pet cuddles (32%). In fact, Americans would rather hear their favorite artist or band over their partner (46% vs 34%) when they need to de-stress. The average American has stuck to their unwinding method for over a decade, which may be because 84% find these approaches effective. The survey, which polled respondents who have all tried CBD or THC before, also found that 20% take CBD gummies and 30% use THC products on a daily basis in order to combat their stress. And it's working: Users find that their stress levels are decreased by an average of 54% after taking a CBD gummy, while THC users find they drop by more than two-thirds (68%). Nearly three in five (58%) respondents believe that there's less stigma surrounding CBD and THC products today, compared to 10 years ago. But compared to just five years ago, two-thirds (67%) find themselves getting stressed easier. This may be why another two-thirds (67%) agree that Americans would be less stressed out if they all indulged in some CBD or THC. "One of the benefits of CBD's interaction with the body's endocannabinoid system is a calming effect that works great for dialing down stress," said Jameson Rodgers, CBDfx Co-Founder. "THC can have similar positive effects-enhanced by the compound's natural mood elevation benefits-making it another great choice for stress relief." Seventy-three percent of Americans say that stress has an impact on their quality of life and an even larger number (77%) said it has an impact on their quality of sleep. In fact, only 20% of Americans admit they don't look at their phone past a certain time each night and even fewer (11%) avoid looking at it before a certain time in the morning. To combat this, the average respondent takes CBD gummies an average of three nights a week, while 16% say it's a nightly occurrence. They also average using THC products four nights each week, with 29% doing so nightly. "Over time, lack of sleep can have a negative effect on many areas of a person's overall health, including stress. When you're tired, stress can be more difficult to manage and, potentially, can do more long-term damage," said Rodgers. "CBD sleep products can be an effective natural sleep aid. Those same calming effects that make CBD great for stress relief also make it an effective base ingredient for sleep aids, along with compounds like CBN (cannabinol), melatonin, chamomile, and other natural ingredients. THC works well with those same natural sleep ingredients, helping to elevate one's mood and help them relax before bedtime." TOP 10 SMALLEST THINGS/SOUNDS THAT CAUSE AMERICANS STRESS When I see someone that I don't want to talk to - 46%A knock on the front door when I'm not prepared for guests - 44%People talking to me when I want silence - 43%When my Wi-Fi is lagging or cuts out - 40%Listening to someone chewing loudly - 40%Phone calls when I'm not expecting one - 34%Someone near me heavy breathing - 25%My alarm clock/alarm - 21%Text message alerts - 16%My phone/notifications going off during a meeting - 15% Survey methodology: Talker Research surveyed 2,000 Americans who've ever tried CBD or THC; the survey was commissioned by CBDfx and administered and conducted online by Talker Research between April 30 and May 8, 2025. We are sourcing from a non-probability frame and the two main sources we use are: Traditional online access panels - where respondents opt-in to take part in online market research for an incentiveProgrammatic - where respondents are online and are given the option to take part in a survey to receive a virtual incentive usually related to the online activity they are engaging in Those who did not fit the specified sample were terminated from the survey. As the survey is fielded, dynamic online sampling is used, adjusting targeting to achieve the quotas specified as part of the sampling plan. Regardless of which sources a respondent came from, they were directed to an Online Survey, where the survey was conducted in English; a link to the questionnaire can be shared upon request. Respondents were awarded points for completing the survey. These points have a small cash-equivalent monetary value. Cells are only reported on for analysis if they have a minimum of 80 respondents, and statistical significance is calculated at the 95% level. Data is not weighted, but quotas and other parameters are put in place to reach the desired sample. Interviews are excluded from the final analysis if they failed quality-checking measures. This includes: Speeders: Respondents who complete the survey in a time that is quicker than one-third of the median length of interview are disqualified as speedersOpen ends: All verbatim responses (full open-ended questions as well as other please specify options) are checked for inappropriate or irrelevant textBots: Captcha is enabled on surveys, which allows the research team to identify and disqualify botsDuplicates: Survey software has "deduping" based on digital fingerprinting, which ensures nobody is allowed to take the survey more than once It is worth noting that this survey was only available to individuals with internet access, and the results may not be generalizable to those without internet access. The post Americans lose it over these tiny everyday annoyances appeared first on Talker. Copyright Talker News. All Rights Reserved.

Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025

Associated Press

time14 hours ago

  • Associated Press

Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025

Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ('Neural' or the 'Company'), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ('CWE'), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks 's fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: 'We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand.' 'We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team.' Mr. Cerveny added: 'This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations.' Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact: Neural Therapeutics Inc. Ian Campbell, CEO E: [email protected] T: +1 (647) 697-NURL (6875) Marc Lakmaaker E: [email protected] T: +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ('FLS') relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expect', 'plan' and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. Persons' (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit

Dangerous discovery made 30cm under Aussie garden: 'Big issues'
Dangerous discovery made 30cm under Aussie garden: 'Big issues'

Yahoo

time2 days ago

  • Yahoo

Dangerous discovery made 30cm under Aussie garden: 'Big issues'

When an Aussie woman dug 30cm deep into her backyard, she was surprised to find it lined with plastic shade cloth. After she shared images on social media, over 100 people responded, with some joking there could be a body underneath. Luckily, it wasn't hiding anything gruesome, but her discovery does point to a big problem buried beneath thousands of gardens. Shade cloth and black plastic have been used as weed mats for decades before we knew any better, and over time, they break down into tiny pieces called microplastics. Not only can they kill worms and be absorbed by plants, they can enter the human body when we eat food contaminated by them. Researchers have found them in brains, male genitals, and even breastmilk. Related: 🩸 'Scary' new disease linked to plastic consumption in Australia Dr Scott Wilson, the research director of the Australian Microplastic Assessment Project and honorary senior research fellow at Macquarie University, explained it's not just the plastics themselves that are a danger to plants and animals. Each could contain a deadly cocktail of chemical contaminants. 'For instance, colour dyes and plasticisers are released as the plastic breaks apart, and they can leach into the soil,' he said. 'The plastics themselves are harmful, but the chemicals are potentially more harmful. Talking generally, they can have a whole range of effects from impacting hormone systems, to reproduction, growth, and development.' Plastics vary greatly in terms of what sort of chemical cocktail they contain, making it hard to predict what their effect on the environment will be. Gardening photos highlight tiny sign trees are riddled with invasive species Warning as 212kg of plastic falls on international city Dirty secret lurking in water near popular Aussie beach If plastic is layered on the surface for a short period it's unlikely to be dangerous. And when it's layered deep in the deoxygenated zone of the soil, it poses less of a risk, because it's slow to break down. But most weed mats are placed closer to the surface where heat and microbes slowly break them up. 'The whole issue with plastics in the environment is they shed. Once they start breaking down they release microplastics. And that's the issue, they don't go away they just disintegrate,' he said. 'They just break up, not down. And they create big issues in your soil long into the future.' Love Australia's weird and wonderful environment? 🐊🦘😳 Get our new newsletter showcasing the week's best stories.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store